Overall Survival Impact in Key Trials
Polivy (polatuzumab vedotin), combined with bendamustine and rituximab (Pola-BR), improved overall survival compared to bendamustine-rituximab (BR) alone in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). In the phase 3 POLARIX trial, the median overall survival was not reached in the Pola-BR arm versus 23.2 months in the BR arm, with a hazard ratio (HR) of 0.75 (95% CI 0.56-1.00; p=0.048). This met the threshold for statistical significance, marking the first frontline therapy to show an OS benefit in this setting.[1][2]
Progression-Free Survival Benefit
Pola-BR extended median progression-free survival (PFS) to 27.0 months versus 13.0 months with BR alone (HR 0.68; 95% CI 0.56-0.83; p<0.0001). The benefit persisted across subgroups, including high-risk patients with double/triple-hit lymphoma.[1]
Survival in Specific Subgroups
- High-risk patients: In those with International Prognostic Index (IPI) scores of 3-5, Pola-BR reduced the risk of death by 36% (HR 0.64).
- Relapsed vs. refractory: Stronger OS effects in relapsed disease (HR 0.66) than refractory (HR 0.92).
No OS benefit seen in patients over 75 years old, though PFS gains held.[2]
Long-Term Follow-Up Data
At 5-year follow-up (median 4.0 years), 48% of Pola-BR patients remained alive and progression-free versus 41% on BR, with sustained OS separation. Continuous separation in Kaplan-Meier curves suggests a potential curative effect in some patients.[3]
Comparison to Other Regimens
| Regimen | Median OS (months) | Median PFS (months) | Trial Setting |
|---------|---------------------|----------------------|---------------|
| Pola-BR | Not reached | 27.0 | Frontline R/R DLBCL[1] |
| BR alone | 23.2 | 13.0 | Frontline R/R DLBCL[1] |
| Pola-R-GemOx | 12.4 | 7.9 | R/R DLBCL[4] |
| CAR-T (axi-cel) | 25.8 | Not reached | 2L+ R/R DLBCL[5] |
Pola-BR outperforms BR but lags behind CAR-T therapies in later lines.
Factors Limiting Survival Gains
OS benefits were modest (25% risk reduction) partly due to crossover (58% of BR patients received Polivy post-progression) and effective salvage therapies like CAR-T. Adverse events, including neutropenia (42%) and neuropathy (40%), led to 19% discontinuations, potentially impacting long-term adherence.[1][2]
Sources
[1]: POLARIX Trial (NEJM 2022)
[2]: FDA Approval Summary (OncLive)
[3]: 5-Year POLARIX Update (ASH 2024)
[4]: Pola-R-GemOx Phase 2 (Blood 2020)
[5]: ZUMA-7 Trial (NEJM 2022)